WO1998022499A2 - Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci - Google Patents

Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci Download PDF

Info

Publication number
WO1998022499A2
WO1998022499A2 PCT/CA1997/000868 CA9700868W WO9822499A2 WO 1998022499 A2 WO1998022499 A2 WO 1998022499A2 CA 9700868 W CA9700868 W CA 9700868W WO 9822499 A2 WO9822499 A2 WO 9822499A2
Authority
WO
WIPO (PCT)
Prior art keywords
anetin
growth
arretin
antagonist
protein
Prior art date
Application number
PCT/CA1997/000868
Other languages
English (en)
Other versions
WO1998022499A3 (fr
WO1998022499A9 (fr
Inventor
Lisa Joan Mckerracher
Samuel David
Peter Erich Braun
Zhi-Cheng Xiao
Original Assignee
Lisa Joan Mckerracher
Samuel David
Peter Erich Braun
Xiao Zhi Cheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lisa Joan Mckerracher, Samuel David, Peter Erich Braun, Xiao Zhi Cheng filed Critical Lisa Joan Mckerracher
Priority to AU50442/98A priority Critical patent/AU5044298A/en
Publication of WO1998022499A2 publication Critical patent/WO1998022499A2/fr
Publication of WO1998022499A3 publication Critical patent/WO1998022499A3/fr
Publication of WO1998022499A9 publication Critical patent/WO1998022499A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • CNS central nervous system
  • CNS myelin The growth inhibitory properties of CNS myelin have been demonstrated in a number of different laboratories by a wide variety of techniques, including plating neurons on myelin substrates or cryostat sections of white matter, and observations of axon contact with mature oligodendrocytes (Schwab et al, 1993). Therefore, it is well documented that adult neurons cannot extend neurites over CNS myelin in vitro.
  • Schwab has sought to determine the identity of the myelin-derived inhibitors of neurite outgrowth, and his findings have been extensively reviewed (Schwab et al, 1993).
  • Schwab determined a possible molecular weight of the growth inhibitory proteins in the following way.
  • Myelin proteins were separated by SDS PAGE under denaturing conditions, the gel was cut into slices and proteins were eluted from the slices and inserted into liposomes. The liposomes were tested for inhibitory activity. Regions of the gel corresponding to 250 kDa and 35 kDa were identified as most inhibitory, and heat destroyed the inhibitory activity. The loss of activity with heat suggested that the activity was due to a protein that required native conformation. Why this putative protein retains biological activity after the denaturing conditions of SDS-PAGE remain a mystery. The evidence to claim the 250 kDa and 35 kDa proteins as the major myelin inhibitors is weak.
  • the evidence for the 250 kDa and 35 kDa proteins as myelin-derived inhibitors comes mainly from the work of Schwab with their IN-1 antibody.
  • Schwab raised monoclonal antibodies to the inhibitory proteins eluted from gels and cloned one monoclonal antibody, called IN-1, which is a low-affinity IgM. It has been used to characterize the myelin-derived inhibition.
  • the antibody is reported to bind to the 35 kDa and 250 kDa proteins, but the Western blots indicate that it lacks specificity and that many additional bands are also recognized (Caroni and Schwab, Neuron, 1, 85-96, 1988).
  • Tenascin-C Four members of the tenascin family have been identified and characterized: tenascin-C, tenascin-R, tenascin-X and tenascin-Y (Bristow et al, Cell Biol., 122, 265-278, 1993; Erickson, H.P., J. Cell Biol., 120, 1079-1081, 1993).
  • Tenascin-X and tenascin-Y are not prominent in the nervous system.
  • Tenascin-C is important in the development of the nervous system and it is the best characterized member of this protein family. It is generated by alternative splicing (Weller et al, J. Cell Biol., 112, 355-362, 1991;
  • Tenascin-R has a modular structure similar to TN-C, previously designated
  • Tenascin-R is predominantly expressed by oligodendrocytes during the onset and early phases of myelin formation and remains detectable in myelin-forming oligodendrocytes in the adult, and is also expressed by neurons (Pesheva et al, 1989; Fuss et al, 1993). Tenascin-R has been shown to be involved in promotion of neurite outgrowth and morpho logical polarization of differentiating neurons when presented as a uniform substrate (Lochter and Schachner, J. Neurosci., 13, 3986-4000, 1993; Lochter et al, Eur. J. Neurosci., 6, 597-606, 1994).
  • tenascin-R When offered as a sharp substrate boundary with a neurite outgrowth conducive molecule, tenascin-R is repellent for growth cone advance (Taylor et al, J. Neurosci. Res., 35, 347-362, 1993; Pesheva et al, 1993).
  • Tenacins are not thought to be an important component of the myelin-derived inhibitory activity because they lack the specific myelin distribution, they are not restricted to the CNS, and their molecular weight differs from the presumptive proteins identified by Schwab.
  • studies have indicated that both tenascin R and tenascin C are minor inhibitory components of octlyglucoside extracts of myelin. The data indicate that growth inhibitory proteins from the CNS matrix may become associated with isolated myelin fragments.
  • CSPGs Chondroitin Sulfate Proteoglycans
  • GAGs Glycosaminoglycans
  • GAGs are polymers of disaccharide repeats, which are mostly highly sulphated and negatively charged.
  • the main glycosaminoglycans in PGs are chondroitin sulfate, dermatan sulfate, heparan sulfate, and keratan sulfate.
  • proteoglycans are known to be important for the development and regeneration of the nervous system, but they have not been considered to be myelin proteins or form part of the growth inhibitory activity of myelin. Moreover, proteoglycans have not been reported to be recognized by the LN-1 antibody or to form a major growth inhibitory component of white matter regions of the CNS.
  • CSPGs Chondroitin sulfate proteoglycans
  • CSPGs throughout the nervous system implicate them in diverse roles in development and in regeneration. After injuries in the adult CNS, CSPGs are thought to be important in the formation of the glial scar. They have been implicated as both positive and negative modulators of axonal growth. Recent observations indicate that DSD-l-PG, a neural chondroitin sulfate proteoglycan, promotes neurite outgrowth of embryonic day
  • NG2 an integral membrane CSPGs expressed on the surface of glial progenitor cells, inhibits neurite growth.
  • the NG2 proteoglycan also inhibits neurite growth after digestion with chondroitinase ABC, indicating that the inhibitory activity is a property of the core protein and not the covalently attached chondroitin sulfate glycosaminoglycan chains (Dou and Levine, J.
  • proteoglycans are a very heterogenous class of proteins with diverse biological activities it is essential that individual, identified proteins be considered. Relevant to the present invention are the proteoglycans phosphocan and versican, because the protein of the present invention, arretin, has common immunological eptitopes with these proteins.
  • Phosphacan is a proteoglycan in brain recognized by the 3F8 antibody (Maurel et al, Proc. Nat. Acad. Sci. USA, 91, 2512-2516, 1994), and by the 6B4 antibody (Maeda et al, Neurosci., 67, 23-35, 1995).
  • Phosphacan is a splice variant of a receptor-type protein tyrosine phosphatase, although phosphacan itself lacks the phosphatase domains. It is a protein with an apparent molecular weight of approximately 500 kDa, having a core glycoprotein of approximately 400 kDa.
  • the HNK-1 monoclonal antibody recognizes a 3-sulphated carbohydrate epitope, and this epitope is strongly represented in phosphacan from 7-day brain, but not in adult brain (Rauch et al, J. Biol. Chem., 266. 14785-14801, 1991).
  • phosphacan is immunostained on radial glia and on neurons (Maeda et al, 1995) and generally it is expressed in both white matter and grey matter regions (Meyer-Puttlitz, et al, J. Comp. Neurol. 366. 44-
  • Versican a CSPG originally isolated from fibroblasts, also called PG-M, has an apparent molecular weight of approximately 900 kDa, with a core protein of approximately300 to 400 kDa (Braunewell et al, Eur. J. Neurosci., 7, 792-804, 1995; Naso et al, 1994).
  • Versican belongs to a family of aggregating CSPGs; other members of the family include the cartilage-derived aggrecan, and two PGs expressed in the nervous system, neurocan and brevican (Dours-Zimmermann and Zimmerermann, J. Biol. Chem., 269, 32992-32998, 1994).
  • Versican is widely distributed in adult human tissues, associated with connective tissue of various organs, in certain muscle tissues, epithelia, and in central and peripheral nervous tissues.
  • versican isoforms are known (Vo, VI, V2, V3), derived by alternative splicing. They vary in calculated mass from approximately 370 kDa (Vo) to approximately 72 kDa (V3). It has been suggested that the association of versican expression with cell migration and proliferation in vivo and its adhesion inhibitory properties in vitro point to pathological processes such as tumorigenesis and metastasis (Bode-Lesniewska et al, Histol. & Cyto., 44, 303-312, 1996; Naso et al,. J. Biol. Chem., 269, 32999-33008, 1994).
  • CSPGs related to versican are brevican (Mr approximately 145 kDa) and neurocan (Mr > 300 kDa). Neither of these is known to be expressed by oligodendrocytes and are therefore not expected to be present in CNS myelin (Engel et al, J. Comp. Neurol. 36 . 6, 34-43, 1996; Yamada et al, J. Biol. Chem., 269, 10119- 10126, 1994).
  • CSPG family member that is not related to either versican or phosphacan, is NG2. Although it is expressed by 02 A progenitor cells in the developing rat nervous system, it has no apparent homo logy to arretin-relevant GSPG's, and has an Mr approximately 400-800 kDa with a core protein of approximately 300 kDa (Nishiyama et al, J. Cell Biol, 114, 359-371, 1991).
  • Neuroblastoma arises from neuroectoderm and contains anaplastic sympathetic ganglion cells (reviewed in Pinkel and Howarth, 1985, In: Medical Oncology, Calabrese, P., Rosenberg, S. A., and Schein, P. S., eds., MacMillan, N.Y., pp. 1226-1257).
  • One interesting aspect of neuroblastoma is that it has one of the highest rates of spontaneous regression among human tumors (Everson, 1964, Ann. N.Y. Acad. Sci. 114:721-735) and a correlation exists between such regression and maturation of benign ganglioneuroma (Bolander, 1977, Am. J. Dis. Child. 122:12-14).
  • Neuroblastoma cells have been found to retain the capacity for morphological maturation in culture. The tumors may occur anywhere along the sympathetic chain, with 50% of such tumors originating in the adrenal medulla.
  • Neuroblastoma affects predominantly preschool aged children and is the most common extracranial solid tumor in childhood, constituting 6.5% of pediatric neoplasms. One half are less than two years of age upon diagnosis. Metastases are evident in 60% of the patients at presentation usually involving the bones, bone marrow, liver, or skin. The presenting symptoms may be related to the primary tumor (spinal coral compression, abdominal mass), metastatic tumor (bone pain) or metabolic effects of substances such as catecholamines or vasoactive polypeptides secreted by the tumor (e.g. hypertension, diarrhea). Experimental evidence indicates that an altered response to NGF is associated with neuroblastoma (Sonnenfeld and Ishii, 1982, J. Neurosci. Res. 8:375-391).
  • NGF stimulated neurite outgrowth in one-half of the neuroblastoma cell lines tested; the other half was insensitive. However, NGF neither reduced the growth rate nor enhanced survival in any neuroblastoma cell line.
  • Present therapies for neuroblastoma involve surgery and/or chemotherapy. Radiation therapy is used for incomplete tumor responses to chemotherapy. There is a 70-100% survival rate in individuals with localized tumors, but only a 20% survival rate in those with metastatic disease even with multiagent chemotherapy. It appears that patients less than one year have a better prognosis (70%) than older children.
  • the present invention relates to a neuron and neural tumor growth regulatory system, antibodies directed against the components of this system and diagnostic, therapeutic, and research uses for each of these aspects.
  • the concept of a system is used to denote the functional relationship between the genes (for the regulatory factors and the receptors), their encoded protein-regulatory factors which regulate neuron growth (particularly neurite growth), and the receptors which are activated by the protein.
  • the functional relationship allows one to use one component to identify and determine another. For example, having identified the protein component (factor or receptor), one can use techniques well known in the art to identify the gene.
  • arretin a protein has now been identified, hereinafter referred to as arretin, as one of the molecular components involved in contact-mediated growth inhibition on myelin.
  • This protein has an apparent molecular weight of approximately 70 kDa, but it could be derived from a molecular complex.
  • procedures for obtaining the other parts of the system are well known to those skilled in the art to purify the other components to the system.
  • the protein can be used in very standard techniques to obtain the amino acid sequence which can be used to obtain probes for nucleic acid sequences encoding arretin.
  • arretin protein may be tagged for use as a reporter to detect receptors of arretin, which are then sequenced and used to obtain probes for the nucleic acid sequences encoding arretin receptors.
  • the production of antibodies to each of these components is also standard procedure.
  • the present invention further relates to arretin receptors and fragments thereof as well as the nucleic acid sequences coding for such arretin receptors and fragments, and their therapeutic and diagnostic uses. Substances which function as either agonists or antagonists to arretin receptors are also envisioned and within the scope of the present invention.
  • the present invention further relates to the nucleic acid sequences coding for arretin and its receptors, in addition to their therapeutic and diagnostic uses.
  • arretin for the regulation of growth of neurons and neural tumors.
  • a method for inhibiting growth of neural tumors comprising the steps of introducing into the growth environment of the neurons a growth inhibiting amount of arretin, fragments thereof, or an arretin agonist.
  • arretin can be used to design small molecules to block neurite outgrowth and neural tumor growth. These small molecules will be useful to block growth in situations involving aberrant sprouting, epilepsy, or metastasis.
  • a further embodiment involves a method of suppressing the inhibition of neuron growth, comprising the steps of delivering to the nerve growth environment, antibodies directed against arretin in an amount effective to reverse said inhibition.
  • arretin in another aspect of the present invention arretin can be used to design antagonist agents that suppress the arretin-neuronal growth regulatory system. These antagonist agents can be used to promote axon regrowth and recovery from trauma or neurodegenerative disease.
  • an assay method useful to identify arretin antagonist agents that suppress inhibition of neuron growth comprising the steps of: a) culturing neurons on a growth permissive substrate that incorporates a growth- inhibiting amount of arretin; and b) exposing the cultured neurons of step a) to a candidate arretin antagonist agent in an amount and for a period sufficient prospectively to permit growth of the neurons; thereby identifying as arretin antagonists the candidates of step b) which elicit neurite outgrowth from the cultured neurons of step a).
  • an assay method useful for screening for compounds that stimulate cell adhesion and neurite growth comprising the steps of: a) coating a growth permissive substrate with a growth-inhibiting amount of arretin; and b) adding a test compound and neuronal cells to the arretin-coated substrate; c) washing to remove unattached cells; d) measuring the viable cells attached to the substrate, thereby identifying the cell adhesion candidates of step b) which elicit neurite outgrowth from the cultured neurons of step a).
  • a method to suppress the inhibition of neurons comprising the steps of delivering, to the nerve growth environment, an antagonist for arretin or its receptor in an amount effective to reverse said inhibition.
  • nucleic acids encoding arretin and/or its receptor can be used in antisense techniques and therapies.
  • Arretin inhibits neurite outgrowth in nerve cells and neuroblastoma cells.
  • Such inhibitory protein comprises a 70,000 dalton molecular weight protein, aggregates, and analogs, derivatives, and fragments thereof.
  • Arretin and its related proteins proteins may be used in the treatment of patients with malignant tumors which include but are not limited to melanoma and nerve tissue tumors (e.g., glioma, or neuroblastoma).
  • the present invention also relates to antagonists of arretin, including, but not limited to, antibodies.
  • Such antibodies can be used to neutralize the neurite growth inhibitory factors for regenerative repair after trauma, degeneration, or inflammation.
  • monoclonal antibody may be used to promote regeneration of nerve fibers over long distances following spinal cord damage.
  • Figure 1 Analysis of growth inhibition after separation of myelin proteins by DEAE anion exchange chromatography.
  • FIG. 3 Western blot analysis of PNA affinity purification of the 70 kDa CSPGs from DEAE chromatographic fractions 20-34.
  • A Pooled DEAE chromatographic fractions 20-34 (lane 1), fractions 2 and 6 (lanes 2 and 3) of Hepes buffer wash, fractions 2 and 6 (lanes 4 and 5) of high salt buffer wash, and fractions 2, 4, 6, and 8 (lanes 6, 7, 8, and 9) were subjected to SDS-PAGE (6-16% acrylamide gradient) under reducing conditions, and detected by Western blots with anti-CS 473 antibody.
  • Figure 4 Identification of the 70 kDa components as phosphacan and versican-related molecules.
  • FIG. 5 Analysis of the 70 kDa CSPGs after chondroitinase ABC treatment.
  • Pooled eluates from the PNA affinity column (lane 1) and chondroitinase ABC treated pooled eluates from PNA affinity column (lane 2) were subjected to SDS-PAGE (6-16% acrylamide gradient) under reducing conditions and detected by amido black staining
  • A and by Western blots with polyclonal anti-phosphacan 3F8 (B).
  • a bands at 28 kDa is PNA (artifactually eluted).
  • Two bands above 72 kDa are chondrontinase ABC. The position and molecular weight in kDa of marker proteins is indicated.
  • FIG. 6 Determination of cell-type expression of the 70 kDa CSPGs.
  • Figure 7 Inhibitory effects of the 70 kDa CSPGs on neurite outgrowth from cerebellar neurons.
  • Cerebellar neurons were plated as single cell suspensions on the 70 kDa CSPGs (arretin) and other substrates applied to PORN-treated nitrocellulose substrates. Cells were maintained for 24 h before fixation and staining with toluidine blue. Error bars indicate standard deviation. Coating concentrations were about 50 nM (1 :25 dilution) and 10 nM (1:125 dilution) for arretin and denatured arretin (DN) and 10 nM for laminin. Bars represent percent neurons with neurites (mean ⁇ SD).
  • Figure 8 Inhibitory effects of the 70 kDa CSPGs on neurite outgrowth from hippocampal neurons. Hippocampal neurons were plated as single cell suspensions on the 70 kDa CSPGs (arretin) and other substrates applied to PORN-treated tissue culture plastic. Cells were maintained for 24 h before fixation and staining with toluidine blue. Error bars indicate standard deviation. Coating concentrations were about 50 nM (1:25 dilution) and 10 nM (1:125 dilution) for arretin and denatured arretin (DN) and 10 nM for laminin. Bars represent percent neurons with neurites (mean ⁇ SD).
  • Figure 9 inhibitory effects of the 70 kDa CSPGs on neurite outgrowth from NG108-15 cells.
  • NG108 cells were plated as single cell suspensions on the 70 kDa CSPGs (arretin; inhib.p) and other substrates applied to PLL-treated tissue culture plastic. Cells were maintained for 24 h before fixation and staining with toluidine blue. Coating concentrations were about 50 nM (1 :5 dilution) for arretin (inhib.p) and denature arretin
  • FIG. 10 SDS-PAGE showing purification of arretin.
  • the polypeptide was visualized by dyes after gel electrophoresis.
  • Lane 1 shows arretin purified by peanut agglutinin (PNA) affinity chromatography. Two bands at approximately 70kDa are visible. A band at 28 kDa was identified as a peanut agglutinin contaminant.
  • Lane 2 shows pooled fractions from a DEAE chromatographic column that were applied to the PNA column for further purification of the arretin bands.
  • Lane 3 shows myelin starting material from which arretin was extracted.
  • Lane 4 shows molecular weight markers.
  • FIG. 11 Two-dimensional gel electrophoresis separation of arretin obtained from PNA column chromatography. Polypeptides were separated in the first dimension by isoelectric focusing followed by SDS-PAGE separation according to size in the second dimension. Spots 1,2, and 3 at approximately 70 kDa are separated from each other by size and charge. The spot at 28 kDa is peanut agglutinin, verified by Western blotting (not shown).
  • Anti-arretin antibody 18D2 neutralizes neurite outgrowth inhibition and cell body repulsion by arretin on NG 108-15 cells.
  • Picture A demonstrates cells growing normally on a substrate of arretin-polylysine overlaid with anti-arretin 18D2.
  • Picture B shows cell growth is inhibited on a substrate of arretin-polylysine treated with control antiserum.
  • 18D2 recognizes the approximately 70 kDa arretin component.
  • Lane 1 (arros) shows partially purified arretin.
  • Lane 2 shows myelin.
  • Lane 3 shows octylglucoside/salt extract of myelin.
  • Figure 14 Growth cone collapse by arretin.
  • A Collapsed growth cones (arrows) after addition of arretin.
  • B Growth cones treated with DMEM as a control remain spread.
  • Explants of P2 rat dorsal root ganglion neurons were plated on laminin can cultured overnight to allow neurite extension.
  • Arretin purified by lectin chromatography (A) or control medium (B) was added to the cultures.
  • the cultures were fixed with paraformaldehyde 30 min. later and viewed by phase contrast microcopy.
  • the numbers of collapsed growth cones were counted. Arretin caused significantly more growth cone collapse than the PBS or DMEM controls.
  • neurite growth regulatory factor refers to either arretin or its receptor.
  • Antist refers to a pharmaceutical agent having biological activity of inhibiting the neurite outgrowth of neurons cultured on a permissive substrate or inhibiting the regeneration of damaged neurons. It would be desirable to inhibit neuron growth in cases of epilepsy, neuroblastoma, and neuromas, a disease state in a mammal which includes neurite outgrowth or other neural growth of an abnormal sort which causes pain at the end of an amputated limb.
  • Antagonists which may be used in accordance with the present invention include without limitation a arretin fragment, an analog of arretin of the arretin fragment, a derivative of either arretin, the arretin fragment or said analog, an anti-idiotypic arretin antibody or a binding fragment thereof, arretin ectodomain and a pharmaceutical agent.
  • Antagonist refers to a pharmaceutical agent which in accordance with the present invention which inhibits at least on biological activity normally associate with arretin, that is blocking or suppressing the inhibition of neuron growth.
  • Antagonists which may be used in accordance with the present invention include without limitation a arretin antibody or a binding fragment of said antibody, a arretin fragment, a derivative of arretin or of a arretin fragment, an analog of arretin or of a arretin fragment or of said derivative, and a pharmaceutical agent, and is further characterized by the property of suppressing arretin-mediated inhibition of neurite outgrowth.
  • An arretin antagonist is therefore, a chemical compound possessing the ability to alter the biological activity of the neuronal receptor for arretin such that growth of neurons or their axons is suppressed.
  • the agonist or antagonist of arretin in accordance with the present invention is not limited to arretin or its derivatives, but also includes the therapeutic application of all agents, referred herein as pharmaceutical agents, which alter the biological activity of the neuronal receptor for arretin such that growth of neurons or their axon is suppressed.
  • the receptor can be identified with know technologies by those skilled in the art (Mason, (1994) Curr. Biol, 4:1158-1161) and its association with arretin or fragments thereof can be determined.
  • the neuronal receptor for arretin may or may not be the same as cell surface molecules that recognize and bind arretin in an adhesion assay (Kelm et al., (1994) Curr. Biol, 4:965-972).
  • an adhesion assay Karlm et al., (1994) Curr. Biol, 4:965-9712.
  • appropriate peptides or their analogs can be designed and prepared to serve as agonist or antagonist of the arretin-receptor interaction.
  • effective amount or “growth-inhibiting amount” refers to the amount of pharmaceutical agent required to produce a desired agonist or antagonist effect of the arretin biological activity.
  • the precise effective amount will vary with the nature of pharmaceutical agent used and may be determined by one or ordinary skill in the art with only routine experimentation.
  • arretin biological activity refers to cellular events triggered by arretin, being of either biochemical or biophysical nature. The following list is provided, without limitation, which discloses some of the known activities associated with contact-mediated growth inhibition of neurite outgrowth, adhesion to neuronal cells, and promotion of neurite out growth from new born dorsal root ganglion neurons.
  • substantially pure or isolated in the present specification and claims as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been separated from their in vivo cellular environment. As a result of this separation and purification, the substantially pure DNAs, RNAs, polypeptides and proteins are useful in ways that the non-separated, impure DNAs, RNAs, polypeptides or proteins are not.
  • biologically active refers to a polypeptide that is able to produce one of the functional characteristics exhibited by arretin or its receptors described herein.
  • biologically active proteins are those that demonstrate inhibitory growth activities central nervous system neurons. Such activity may be assayed by any method known to those of skill in the art.
  • arretin is a growth inhibitory protein in myelin
  • the description of the present invention comprising a neuron and neural tumor growth regulatory system can be divided into the following sections solely for the purpose of description: (1) isolation, purification and characterization of arretin; (2) production of arretin-related derivatives, analogs, and peptides; (3) arretin antagonists and assay methods to identify arretin antagonists; (4) characterization of arretin receptors; (5) molecular cloning of genes or gene fragments encoding arretin and its receptors; (6) generation of arretin related derivatives, analogs, and peptides; (7) production of antibodies against the components of the arretin growth regulatory system, (ie. arretin, its receptors, and the nucleic acid sequences coding for these proteins); (8) the diagnostic, therapeutic and research uses for each of these components and the antibodies directed thereto.
  • the present invention relates to CNS myelin associated inhibitory proteins of neurite growth and receptors of CNS myelin associated inhibitory proteins of neurite growth.
  • the CNS myelin associated inhibitory proteins of the invention may be isolated by first isolating myelin and subsequent purification therefrom. Isolation procedures which may be employed are described more fully in the sections which follow. Alternatively, the CNS myelin associated inhibitory proteins may be obtained from a recombinant expression system. Procedures for the isolation and purification of receptors for the
  • CNS myelin associated inhibitory proteins are described below.
  • Arretin proteins can be isolated from the CNS myelin of higher vertebrates including, but not limited to, birds or mammals (both human and nonhuman such as bovine, rat, porcine, chick, etc.).
  • Myelin can be obtained from the optic nerve or from central nervous system tissue that includes but is not limited to spinal cords or brain stems. The tissue may be homogenized using procedures described in the art (Colman et al., 1982, J. Cell Biol. 95:598-608). The myelin fraction can be isolated subsequently also using procedures described (Colman et al., 1982, supra).
  • the CNS myelin associated inhibitory proteins can be solubilized in detergent (for e.g., see McKerracher et al., 1994).
  • the solubilized proteins can subsequently be purified by various procedures known in the art, including but not limited to chromatography (e.g., ion exchange, affinity, and sizing chromatography), centrifugation, electrophoretic procedures, differential solubility, or by any other standard technique for the purification of proteins.
  • the solubilized proteins can be subjected to one or two-dimensional electrophoresis, followed by elution from the gel. Gel-eluted proteins can be further purified and/or used to generate antibodies.
  • the CNS myelin associated inhibitory proteins may be isolated and purified using immunological procedures.
  • the proteins can first be solubilized using detergent. The proteins may then be isolated by immunoprecipitation with antibodies.
  • the CNS myelin associated inhibitory proteins may be isolated using inimunoaffinity chromatography in which the proteins are applied to an antibody column in solubilized form.
  • derivatives, analogs, and peptides related to arretin are also envisioned, and within the scope of the present invention and include molecules antagonistic to neurite growth regulatory factors (for example, and not by way of limitation, anti-idiotype antibodies).
  • Such derivatives, analogs, or peptides which have the desired inhibitory activity can be used, for example, in the treatment of neuroblastoma.
  • Derivatives, analogs, or peptides related to a neurite growth regulatory factor can be tested for the desired activity by assays for nonpermissive substrate effects or for growth cone collapse.
  • the neurite growth regulatory factor-related derivatives, analogs, and peptides of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level.
  • a cloned neurite growth regulatory factor gene can be modified by any of numerous strategies known in the art (Maniatis, et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
  • a given neurite growth regulatory factor sequence can be cleaved at appropriate sites with restriction endonuclease(s), subjected to enzymatic modifications if desired, isolated, and ligated in vitro.
  • a given neurite growth regulatory factor gene can be mutated in vitro or in vivo, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification.
  • Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site-directed mutagenesis (Hutchinson, et al., 1978, J. Biol. Chem. 253:6551), use of TAB.RTM. linkers (Pharmacia), etc.
  • suitable as arretin antagonist candidates are developed comprising fragments, analogs and derivatives of arretin. Such candidates may interfere with arretin-mediated growth inhibition as competitive but non-functional mimics of endogenous arretin. From the amino acid sequence of arretin and from the cloned DNA coding for it, it will be appreciated that arretin fragments can be produced either by peptide synthesis or by recombinant DNA expression of either a truncated domain of arretin, or of intact arretin could be prepared using standard recominant procedures, that can then be digested enzymically in either a random or a site-selective manner.
  • Analogs of arretin or arretin fragments can be generated also by recombinant DNA techniques or by peptide synthesis, and will incorporate one or more, e.g. 1-5, L- or D- amino acid substitutions.
  • Derivatives of arretin, arretin fragments and arretin analogs can be generated by chemical reaction of the parent substance to incorporate the desired derivatizing group, such as N-terminal, C-terminal and intra-residue modifying groups that have the effect of masking or stabilizing the substance or target amino acids within it.
  • candidate arretin antagonists include those that are derived from a determination of the functionally active region(s) of arretin.
  • the antibodies mentioned above and any others to be prepared against epitopes in arretin when found to be function-blocking in in vitro assays, can be used to map the active regions of the polypeptide as has been reported for other proteins (for example, see Fahrig et al., (1993) Europ., J. Neurosci., 5: 1118-1126; Tropak et al, (1994) J. Neurochem., 62: 854-862).
  • it can be determined which regions of arretin are recognized by neuronal receptors and/or are involved in inhibition of neurite outgrowth.
  • synthetic peptides can be prepared to be assayed as candidate antagonists of the arretin effect.
  • Derivatives of these can be prepared, including those with selected amino acid substitutions to provide desirable properties to enhance their effectiveness as antagonists of the arretin candidate functional regions of arretin can also be determined by the preparation of altered forms of the arretin domains using recombinant DNA technologies to produce deletion or insertion mutants that can be expressed in various cell types as chimaeric proteins that contain the Fc portion of immunoglobulin G (Kelm et al., (1994) Curr. Biol, 4: 965-972).
  • candidate mutant forms of arretin can be expressed on cell surfaces by transfection of various cultured cell types. All of the above forms of arretin, and forms that may be generated by technologies not limited to the above, can be tested for the presence of functional regions that inhibit or suppress neurite outgrowth, and can be used to design and prepare peptides to serve as antagonists.
  • the arretin antagonist is formulated as a pharmaceutical composition which contains the arretin antagonist in an amount effective to suppress arretin-mediated inhibition of nerve growth, in combination with a suitable pharmaceutical carrier.
  • Such compositions are useful, in accordance with another aspect of the invention, to suppress arretin-inhibited nerve growth in patients diagnosed with a variety of neurological disorder, conditions and ailments of the PNS and the CNS where treatment to increase neurite extension, growth, or regeneration is desired, e.g., in patients with nervous system damage.
  • Patients suffering from traumatic disorders including but not limited to spinal cord injuries, spinal cord lesions, surgical nerve lesions or other CNS pathway lesions
  • damage secondary to infarction, infection, exposure to toxic agents, malignancy, paraneoplastic syndromes, or patients with various types of degenerative disorders of the central nervous system can be treated with such arretin antagonists.
  • arretin antagonists may be used to promote the regeneration of CNS pathways, fiber systems and tracts.
  • Administration of antibodies directed to an epitope of arretin, or the binding portion thereof, or cells secreting such antibodies can also be used to inhibit arretin function in patients.
  • the arretin antagonist is used to promote the regeneration of nerve fibers over long distances following spinal cord damage.
  • the invention provides an assay method adapted to identify arretin antagonists, that is agents that block or suppress the growth-inhibiting action of arretin.
  • the assay is a tissue culture assay that measures neurite out-growth as a convenient end-point, and accordingly uses nerve cells that extend neurites when grown on a permissive substrate.
  • Nerve cells suitable in this regard include neuroblastoma cells of the NG108 lineage, such as NG108-15, as well as other neuronal cell lines such as PC 12 cells (American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 USA, ATCC accession NO.
  • CRL 1721 human neuroblastoma cells
  • primary cultures of CNS or PNS neurons taken from embryonic, postnatal or adult animals are cultured on a growth permissive substrate, such as polylysine or laminin, that is over-layed with a growth-inhibiting amount of arretin.
  • the arretin incorporated in the culture is suitably myelin-extracted arretin, although forms of arretin other than endogenous forms can be used provided they exhibit the arretin property of inhibiting neuron growth when added to a substrate that is otherwise growth permissive.
  • candidate arretin antagonists i.e., compounds that block the growth- inhibiting effect of arretin
  • the arretin-containing tissue culture preferably in amount sufficient to neutralize the arretin growth-inhibiting activity, that is between 1.5 and 15 ⁇ g of arretin antagonists per well containing a density of 1000 NG108-15 cells/well cultured for 24 hr. in Dulbecco's minimal essential medium.
  • the culture is evaluated for neurite outgrowth, and arretin antagonists are thereby revealed as those candidates which elicit neurite outgrowth.
  • candidates selected as arretin antagonists are those which elicit neurite outgrowth to a statistically significant extent compared to neurons plated on arretin alone.
  • Arretin not only prevents neurite growth but also reduces the adhesion of cells to the substrate. Since cell adhesion is technically far easier to assay quantitatively than neurite growth, cell adhesion can be used as a first screen for high-through-put screening of a large number of compounds. This can be done using the MTT [3 ⁇ 4-5- dimethylthiazol-2-yl]-2,5-diphenyltertrazolium bromide) assay. MTT is taken up by live cells and converted by the mitochondria into a blue substrate that can be quantified by a densitometer. For this assey, 96-well plates are coated with arretin. After washing wells the add chemical compounds can be added to the well for 1-2 hours or along with neuronal cells such as NG108-15 cells. After 2-4 hours or overnight incubation with the cells, the cultures are washed to remove unattached cells.
  • MTT [3 ⁇ 4-5- dimethylthiazol-2-yl]-2,5-diphenyltertrazolium
  • MTT is then added to the cells at a concentration of 0.5mg/ml in culture medium. Incubate for 4 hours at 37oC in a 5% CO 2 incubator. Wash once with PBS and add acid isopropanol (lOOul/well), and mix with a pipette. After 5 minutes the plates are read with ELISA reader at 550nm.
  • assay tests include without limitation the following: 1) The growth cone collapse assay that is used to assess growth inhibitory activity of collapsin (Raper, J.A., and Kapfhammer, J.P., (1990) Neuron, 2:21-29; Luo et al., (1993) Cell,
  • the ability of the neurons to extend neurites on the transfected cells is assessed (Mukhopadhyay et al, (1994) Neuron, 13:757-767). 4) The use of sections of tissue, such as sections of CNS white matter, to assess molecules that may modulate growth inhibition (Carbonetto et al., (1987) J. Neuroscience, 7:610-620; Savlo, T. and Schwab, M.E., (1989) J. Neurosci., 9:1126-1133). 5) Neurite retraction assays whereby test substrates are applied to differentiated neural cells for their ability to induce or inhibit the retraction of previously extended neurites (Jalnink et al., (1994) J. Cell Bio., 126:801-810; Sudan, H.S. et al., (1992) Neuron, 8:363-375; Smalheiser, N. (1993) J.
  • Useful arretin antagonists include antibodies to arretin and the binding fragments of those antibodies. Antibodies which are either monoclonal or polyclonal can be produced which recognize arretin and its various epitopes using now routine procedures. For the raising of antibody, various host animals can be immunized by injection with arretin or fragment thereof, including but not limited to rabbits, mice, rats, etc.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinmitrophenol, and potentially useful human adjuvants such as BCG (Bacille Calmette-Guerin).
  • Freund's complete and incomplete
  • mineral gels such as aluminum hydroxide
  • surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinmitrophenol
  • BCG Bacille Calmette-Guerin
  • Receptors for arretin can be isolated from cells whose attachment, spreading, growth and/or motility is inhibited by arretin. Such cells include but are not limited to fibroblasts and neurons. In a preferred embodiment, neurons are used as the source for isolation and purification of the receptors.
  • receptors to arretin may be isolated by affinity chromatography of neuronal plasma membrane fractions, in which a myelin associated inhibitory protein or peptide fragment thereof is immobilized to a solid support.
  • receptor cDNA may be isolated by expression cloning using purified arretin as a ligand for the selection of receptor-expressing clones.
  • arretin protein may be tagged for use as a reporter to detect receptors of arretin, using techniques that are well known in the art. There are many different types of tags that may be employed such as flourescence radioactive tags.
  • Any mammalian cell can potentially serve as the nucleic acid source for the molecular cloning of the genes encoding arretin or its receptors.
  • the DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA "library”), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired mammalian cell. (See, for example, Maniatis et al.,
  • Clones derived from genomic DNA may contain regulatory and intron DNA regions, in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, a given neurite growth regulatory factor gene should be molecularly cloned into a suitable vector for propagation of the gene.
  • DNA fragments are generated, some of which will encode the desired neurite growth regulatory factor gene.
  • the DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication.
  • the linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.
  • identification of the specific DNA fragment containing a neurite growth regulatory factor gene may be accomplished in a number of ways. For example, if an amount of a neurite growth regulatory factor gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961-3965).
  • a portion of a neurite growth regulatory factor amino acid sequence can be used to deduce the DNA sequence, which DNA sequence can then be synthesized as an oligonucleotide for use as a hybridization probe.
  • nucleic acid fractions enriched in neurite growth regulatory factor may be used as a probe, as an initial selection procedure. It is also possible to identify an appropriate neurite growth regulatory factor-encoding fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection on the basis of the properties of the gene, or the physical, chemical, or immunological properties of its expressed product, as described above, can be employed after the initial selection.
  • a neurite growth regulatory factor gene can also be identified by mRNA selection using nucleic acid hybridization followed by in vitro translation or translation in Xenopus oocytes.
  • oocytes are injected with total or size fractionated CNS mRNA populations, and the membrane-associated translation products are screened in a functional assay (3T3 cell spreading). Preadsorption of the RNA with complementary DNA (cDNA) pools leading to the absence of expressed inhibitory factors indicates the presence of the desired cDNA. Reduction of pool size will finally lead to isolation of a single cDNA clone.
  • DNA fragments can be used to isolate complementary mRNAs by hybridization.
  • Such DNA fragments may represent available, purified neurite growth regulatory factor DNA, or DNA that has been enriched for neurite growth regulatory factor sequences.
  • Immunoprecipitation analysis or functional assays of the in vitro translation products of the isolated mRNAs identifies the mRNA and, therefore, the cDNA fragments that contain neurite growth regulatory factor sequences.
  • An example of such a functional assay involves an assay for nonpermissiveness in which the effect of the various translation products on the spreading of 3T3 cells on a polylysine coated tissue culture dish is observed.
  • specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against a neurite growth regulatory factor protein.
  • a radiolabeled neurite growth regulatory factor cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template.
  • the radiolabeled mRNA or cDNA may then be used as a probe to identify the neurite growth regulatory factor DNA fragments from among other genomic DNA fragments.
  • Alternatives to isolating the neurite growth regulatory factor genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the neurite growth regulatory factor gene. Other methods are possible and within the scope of the invention.
  • the identified and isolated gene or cDNA can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used.
  • Possible vectors include, but are not limited to, cosmids, plasmids or modified viruses, but the vector system must be compatible with the host cell used.
  • Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives.
  • Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc.
  • the neurite growth regulatory factor gene may be identified and isolated after insertion into a suitable cloning vector, in a "shot gun" approach. Enrichment for a given neurite growth regulatory factor gene, for example, by size fractionation or subtraction of cDNA specific to low neurite growth regulatory factor producers, can be done before insertion into the cloning vector.
  • DNA may be inserted into an expression vector system, and the recombinant expression vector containing a neurite growth regulatory factor gene may then be detected by functional assays for the neurite growth regulatory factor protein.
  • the neurite growth regulatory factor gene is inserted into a cloning vector which can be used to transform, transfect, or infect appropriate host cells so that many copies of the gene sequences are generated. This can be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.
  • linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.
  • the cleaved vector and neurite growth regulatory factor gene may be modified by homopolymeric tailing.
  • Identification of the cloned neurite growth regulatory factor gene can be accomplished in a number of ways based on the properties of the DNA itself, or alternatively, on the physical, immunological, or functional properties of its encoded protein.
  • the DNA itself may be detected by plaque or colony nucleic acid hybridization to labeled probes (Benton, W. and Davis, R., 1977, Science 196:180; Grunstein, M. and Hogness, D., 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961).
  • the presence of a neurite growth regulatory factor gene may be detected by assays based on properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that inhibits in vitro neurite outgrowth. If an antibody to a neurite growth regulatory factor is available, a neurite growth regulatory factor protein may be identified by binding of labeled antibody to the putatively neurite growth regulatory factor-synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.
  • ELISA enzyme-linked immunosorbent assay
  • transformation of host cells with recombinant DNA molecules that incorporate an isolated neurite growth regulatory factor gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene.
  • the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.
  • the recombinant DNA molecule that incorporates a neurite growth regulatory factor gene can be modified so that the gene is flanked by virus sequences that allow for genetic recombination in cells infected with the virus so that the gene can be inserted into the viral genome.
  • the neurite growth regulatory factor DNA-containing clone After the neurite growth regulatory factor DNA-containing clone has been identified, grown, and harvested, its DNA insert may be characterized as described herein.
  • promoter DNA may be ligated 5' of a neurite growth regulatory factor coding sequence, in addition to or replacement of the native promoter to provide for increased expression of the protein. Many manipulations are possible, and within the scope of the present invention.
  • the nucleotide sequence coding for a neurite growth regulatory factor protein or a portion thereof can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence.
  • the necessary transcriptional and translation signals can also be supplied by the native neurite growth regulatory factor gene and/or its flanking regions.
  • a variety of host- vector systems may be utilized to express the protein-coding sequence.
  • mammalian cell systems infected with virus e.g., vaccinia virus, adenovirus, etc.
  • insect cell systems infected with virus e.g., baculovirus
  • microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.
  • the expression elements of these vectors vary in their strengths and specificities. Depending on the host- vector system utilized, any one of a number of suitable transcription and translation elements may be used. Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinations (genetic recombination).
  • Expression vectors containing neurite growth regulatory factor gene inserts can be identified by three general approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences.
  • the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences that are homologous to an inserted neurite growth regulatory factor gene.
  • the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector.
  • certain "marker" gene functions e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
  • recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based on the physical, immunological, or functional properties of a given neurite growth regulatory factor gene product.
  • the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
  • a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered neurite growth regulatory factor protein may be controlled.
  • different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian (e.g. COS) cells can be used to ensure "native" glycosylation of the heterologous neurite growth regulatory factor protein.
  • different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extents.
  • the gene product can be purified and analyzed as described above.
  • the amino acid sequence of arretin and its receptor protein can be deduced from the nucleotide sequence of the cloned gene, allowing the protein, or a fragment thereof, to be synthesized by standard chemical methods known in the art (e.g., see HunkapiUer, et al., 1984, Nature 310:105-111).
  • such neurite growth regulatory factor proteins include but are not limited to those containing altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change.
  • one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
  • Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amno acid belongs.
  • the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine, and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
  • neurite growth regulatory factor proteins which are differentially modified during or after translation, e.g., by glycosylation, proteolytic cleavage, etc.
  • the structure of a given neurite growth regulatory factor gene can be analyzed by various methods known in the art.
  • the cloned DNA or cDNA corresponding to a given neurite growth regulatory factor gene can be analyzed by methods including but not limited to Southern hybridization (Southern, 1975, J. Mol. Biol. 98:503-517), Northern hybridization (Alwine, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5350-5354; Wahl, et al., 1987, Meth. Enzymol. 152:572-581), restriction endonuclease mapping (Maniatis, et al., 1982, Molecular loning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor,
  • DNA sequence analysis can be performed by any techniques known in the art including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467), or use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, Calif.).
  • Antibodies can be produced which recognize neurite growth regulatory factors or related proteins. Such antibodies can be polyclonal or monoclonal. Various procedures known in the art may be used for the production of polyclonal antibodies to epitopes of a given neurite growth regulatory factor. For the production of antibody, various host animals can be immunized by injection with a neurite growth regulatory factor protein, or a synthetic protein, or fragment thereof, including but not limited to rabbits, mice, rats, etc.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.
  • a monoclonal antibody to an epitope of a neurite growth regulatory factor can be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture.
  • the procedure described . may be used to obtain mouse monoclonal antibodies which recognize anetin and its receptors.
  • the monoclonal antibodies for therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies.
  • Human monoclonal antibodies may be made by any of numerous techniques known in the art (.RTM..q., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:7308-7312; Kozbor et al, 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16).
  • Chimeric antibody molecules may be prepared containing a mouse antigen-binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851,
  • a molecular clone of an antibody to a neurite growth regulatory factor epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) may be used to construct nucleic acid sequences which encode a monoclonal antibody olecule, or antigen binding region thereof.
  • a monoclonal antibody to an epitope of anetin can be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by K ⁇ ler and Milstein ((1975) Nature, 256:495-497), and the more recent human B cell hybridoma technique (Kozbor et al., (1983) Immunology Today, 4:72) and EBV-hybridoma technique (Cole et al., (1985) In Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp 77-96). In a particular embodiment, the procedure described by Nobile-Orazio et al.
  • the monoclonal antibodies for therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies.
  • Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g. Tan et al., (1983) Proc. Natl. Acad. Sci. U.S.A., 80: 7308-7312; Kozbor et al, (1983) Immunology Today, 4: 72-79; Olsson et al, (1982) Meth. Enzymol, 92: 3-16,).
  • Chimeric antibody molecules may be prepared containing a mouse antigen-binding domain with human contact regions (Morrision et al., (1984) Proc. Natl. Acad. Sci.
  • a molecular clone of an antibody to a Anetin epitope can be prepared by known techniques. Recombinant DNA methodology may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof (see e.g., Maniatis et al., (1982) In Molecular Cloning, A Laboratory Manual,
  • anetin antibody molecules may be purified by known techniques, such as immunoabsorption or immunoaffinity chromatography, chromotographic methods such as HPLC (high performance liquid chromatography), or a combination thereof, etc.
  • Anetin antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • such fragments include but are not limited to: the
  • F (ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab, fragments which cen be generated by reducing the disulfide bridges of the F (ab') 2 fragment, and the two Fab or Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
  • Monoclonal antibodies known to react with human anetin may be tested for their usefulness to serve as anetin antagonists (Nobile-Orazio et al., (1984) Neurology, 34: 1336-1342; Doberson et al., (1985) Neurochem. Res., 10: 499-513).
  • Antibody molecules may be purified by known techniques, e.g., immunoabsorption or immunoaffmity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), or a combination thereof, etc.
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • fragments include but are not limited to: the F(ab').sub.2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab, fragments which can be generated by reducing the disulfide bridges of the F(ab').sub.2 fragment, and the 2 Fab or Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
  • Anetin, its receptors, analogs, derivatives, and subsequences thereof, and anti-inhibitory protein antibodies or peptides have uses in diagnostics.
  • Such molecules can be used in assays such as immunoassays to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting neurite growth extension, invasiveness, and regeneration. In one embodiment of the invention, these molecules may be used for the diagnosis of malignancies.
  • the CNS myelin associated inhibitory proteins, analogs, derivatives, and subsequences thereof and antibodies thereto may be used to monitor therapies for diseases and conditions which ultimately result in nerve damage; such diseases and conditions include but are not limited to CNS trauma, (e.g.
  • such molecules may be used to detect an increase in neurite outgrowth as an indicator of CNS fiber regeneration.
  • the absence of the CNS myelin associated inhibitory proteins in a patient sample containing CNS myelin can be a diagnostic marker for the presence of a malignancy, including but not limited to glioblastoma, neuroblastoma, and melanoma, or a condition involving nerve growth, invasiveness, or regeneration in a patient.
  • the absence of the inhibitory proteins can be detected by means of an immunoassay in which the lack of any binding to anti-inhibitory protein antibodies is observed.
  • the immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, precipitation reactions, gel diffusion precipitation reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, immunoelectrophoresis assays, and immunohistochemistry on tissue sections, to name but a few.
  • radioimmunoassays ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, precipitation reactions, gel diffusion precipitation reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, immunoelectrophoresis as
  • anetin and related compounds that retain the anetin property of inhibiting neurone growth are used therapeutically to treat conditions in which suppression of undesirable neuronal growth is desired.
  • anetin agonists include for example the treatment of tumors of nerve tissue and of conditions resulting from uncontrolled nerve sprouting such as is associated with epilepsy and in the spinal cord after nerve injury.
  • patients with neuroblastoma, and particularly with neuropathies associated with circulating anetin antibody can be treated with anetin or arretin agonist.
  • compositions that contain, in an amount effective to suppress nerve growth, either anetin or a anetin agonist in combination with an acceptable carrier.
  • Anetin can be obtained either by extraction from myelin as described above or, more practically, by recombinant DNA expression of Anetin-encoding DNA, for example, in the manner reported for MAG by Attia S., et al., J. Neurochem.,61, 718-726, 1993.
  • Useful arretin agonists are those compounds which, when added to the permissive substrate described above, suppress the growth of neuronal cells.
  • Particularly useful Anetin agonists are those compounds which cause a statistically significant reduction in the number of neuronal cells that extend neurites, relative to control cells not exposed to the agonist.
  • Candidate Anetin agonists include fragments of Anetin that incorporate the ectodomain, including the ectodomain /?er se and other N- and/or C-terminally truncated fragments of Anetin or the ectodomain, as well as analogs thereof in which amino acids, e.g. from 1 to 10 residues, are substituted, particularly conservatively, and derivatives of Anetin or Anetin fragments in which the N- and/or C-terminal residues are derivatized by chemical stabilizing groups.
  • amino acids e.g. from 1 to 10 residues
  • Anetin agonists can also include anti-idiotypes of Anetin antibodies and their binding fragments.
  • candidate Anetin agonists include specific regions of the Anetin molecule, and analogs or derivatives of these. These can be identified by using the same technologies described above for identification of Anetin regions that serve as inhibitors of neurite outgrowth.
  • Anetin related derivatives, analogs, and fragments of the invention can be produced by various methods known in the art.
  • the manipulations which result in their production can occur at the gene or protein level.
  • Anetin-encoding DNA can be modified by any of numerous strategies known in the art (Maniatis et al, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982), such as by cleavage at appropriate sites with restriction endonuclease(s), subjected to enzymatic modifications if desired, isolated, and ligated in-vitro.
  • the Anetin-encoding gene can be mutated in-vitro or in-vivo for instance in the manner applied fro production of the ectodomain, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in-vitro modification.
  • Any technique for mutagenesis known in the art cab be used, including but not limited to, in-vitro site directed mutagenesis (Hutchinson, et al, J. Biol. Chem., 253, 6551, 1978), use of TABTM linkers (Pharmacia), etc.
  • Anetin agonist or Anetin antagonist For delivery of Arretin, Anetin agonist or Anetin antagonist, various known delivery systems can be used, such as encapsulation in liposmes or semipermeable membranes, expression in suitably transformed or transfection glial cells, oligodendroglial cells, fibroblasts, etc. according to the procedure known to those skilled in the are (Lindvall et al, Cun. Opinion Neurobiol., 4, 752-757, 1994). Linkage to ligands such as antibodies can be used to target delivery to myelin and to other therapeutically relevant sites in-vivo.
  • Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, and intranasal routes, and transfusion into ventricles or a site of operation (e.g. for spinal cord lesions) or tumor removal.
  • cells secreting Anetin antagonist activity for example, and not by way of limitation, hybridoma cells encapsulated in a suitable biological membrane may be implanted in a patient so as to provide a continuous source of Anetin inhibitor.
  • ligands which bind to anetin or its receptors can be used in imaging techniques.
  • small peptides e.g., inhibitory protein receptor fragments
  • imaging techniques such as PET (positron emission tomography) diagnosis or scintigraphy detection, under conditions noninvasive to the patient.
  • Neurite growth inhibitory factor genes DNA, cDNA, and RNA, and related nucleic acid sequences and subsequences, including complementary sequences, can also be used in hybridization assays.
  • the neurite growth inhibitory factor nucleic acid sequences, or subsequences thereof comprising about at least 15 nucleotides, can be used as hybridization probes.
  • Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with changes in neurite growth inhibitory factor expression as described supra.
  • total RNA in myelin, e.g., on biopsy tissue sections, from a patient can beassayed for the presence of neurite growth inhibitory factor mRNA, where the amount of neurite growth inhibitory factor mRNA is indicative of the level of inhibition of neurite outgrowth activity in a given patient.
  • CNS myelin associated inhibitory proteins of the present invention can be therapeutically useful in the treatment of patients with malignant tumors including, but not limited to melanoma or tumors of nerve tissue (e.g. neuroblastoma).
  • patients with neuroblastoma can be treated with anetin or analogs, derivatives, or subsequences thereof, and the human functional equivalents thereof, which are inhibitors of neurite extension.
  • derivatives, analogs, or subsequences of CNS myelin inhibitory proteins which inhibit the native inhibitory protein function can be used in regimens where an increase in neurite extension, growth, or regeneration is desired, e.g., in patients with nervous system damage.
  • Patients suffering from traumatic disorders including but not limited to spinal cord injuries, spinal cord lesions, or other CNS pathway lesions), surgical nerve lesions, damage secondary to infarction, infection, exposure to toxic agents, malignancy, paraneoplastic syndromes, or patients with various types of degenerative disorders of the central nervous system (Cutler, 1987, In: Scientific American Medicines v. 2, Scientific American Inc., N.Y., pp. 11-1-11-13) can be treated with such inhibitory protein antagonists.
  • Such disorders include but are not limited to Alzheimer's Disease, Parkinsons' Disease,
  • Such antagonists may be used to promote the regeneration of CNS pathways, fiber systems and tracts.
  • Administration of antibodies directed to an epitope of, (or the binding portion thereof, or cells secreting such as antibodies) can also be used to inhibit anetin protein function in patients.
  • antibodies directed to anetin may be used to promote the regeneration of nerve fibers over long distances following spinal cord damage.
  • anetin, related molecules, or antibodies thereto e.g., encapsulation in liposomes or semipermeable membranes, expression by bacteria, etc.
  • Linkage to ligands such as antibodies can be used to target myelin associated protein-related molecules to therapeutically desirable sites in vivo.
  • Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, and intranasal routes, and infusion into ventricles or a site of operation (e.g. for spinal cord lesions) or tumor removal.
  • cells secreting CNS myelin inhibitory protein antagonist activity for example, and not by way of limitation, hybridoma cells, encapsulated in a suitable biological membrane may be implanted in a patient so as to provide a continuous source of anti-CNS myelin inhibiting protein antibodies.
  • any method which results in decreased synthesis of anetin or its receptors may be used to diminish their biological function.
  • agents toxic to the cells which synthesize anetin and/or its receptors e.g. oligodendrocytes
  • Anetin receptors as well as analogs, derivatives, and subsequences thereof, and anti-receptor antibodies have uses in diagnostics.
  • These molecules of the invention can be used in assays such as immunoassays or binding assays to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting neurite growth, extension, invasion, and regeneration. For example, it is possible that a lower level of expression of these receptors may be detected in various disorders associated with enhanced neurite sprouting and plasticity or regeneration such as those involving nerve damage, infarction, degenerative nerve diseases, or malignancies.
  • the CNS myelin associated inhibitory protein receptors, analogs, derivatives, and subsequences thereof may also be used to monitor therapies for diseases and disorders which ultimately result in nerve damage, which include but are not limited to CNS trauma (e.g. spinal cord injuries), stroke, degenerative nerve diseases, and for malignancies.
  • CNS trauma e.g. spinal cord injuries
  • stroke e.g. stroke
  • degenerative nerve diseases e.g. stroke, degenerative nerve diseases, and for malignancies.
  • the assays which can be used include but are not limited to those described above.
  • Anetin receptor genes and related nucleic acid sequences and subsequences, including complementary sequences, can also be used in hybridization assays, to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with changes in neurite growth inhibitory factor receptor expression.
  • Anetin receptors or fragments thereof, and antibodies thereto can be therapeutically useful in the treatment of patients with nervous system damage including but not limited to that resulting from CNS trauma (e.g., spinal cord injuries), infarction, or degenerative disorders of the central nervous system which include but are not limited to Alzheimer's disease, Parkinson's disease, Huntington's Chorea, amyotrophic lateral sclerosis, or progressive supranuclear palsy.
  • CNS trauma e.g., spinal cord injuries
  • infarction e.g., spinal cord injuries
  • degenerative disorders of the central nervous system which include but are not limited to Alzheimer's disease, Parkinson's disease, Huntington's Chorea, amyotrophic lateral sclerosis, or progressive supranuclear palsy.
  • anetin receptors, or subsequences or analogs thereof which contain the inhibitory protein binding site can be administered to a patient to "compete out" binding of the inhibitory proteins to their natural receptor, and to thus promote nerve growth or regeneration in the
  • Patients in whom such a therapy may be desired include but are not limited to those with nerve damage, stroke, or degenerative disorders of the central nervous system as described supra.
  • Various delivery systems are known and can be used for delivery of arretin receptors, related molecules, or antibodies thereto, e.g., encapsulation in liposomes, expression by bacteria, etc.
  • Linkage to ligands such as antibodies can be used to target anetin-related molecules to therapeutically desirable sites in vivo.
  • Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, intranasal routes, and infusion into ventricles or a site of tumor removal.
  • the present invention is directed to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic uses of such proteins.
  • the proteins of the present invention include proteins associated with central nervous system myelin with highly nonpermissive substrate properties, termed herein neurite growth inhibitory factors.
  • the present invention is also directed to antibodies to and peptide fragments and derivatives of the neurite growth inhibitory proteins and their therapeutic and diagnostic uses. These antibodies or peptides can be used in the treatment of nerve damage resulting from, e.g., trauma (e.g., spinal cord injuries), stroke, degenerative disorders of the central nervous system, etc.
  • antibodies to anetin proteins may be used to promote regeneration of nerve fibers.
  • monoclonal antibodies directed to arretin and/or its receptors may be used to promote the regeneration of nerve fibers over long distances following spinal cord damage.
  • Example I Isolation and characterization of a novel neurite growth inhibitory molecule from mammalian central nervous system myelin
  • the following lectins were purchased from Sigma: Madura pomifera (osage orange), Arachis hypogaea (PNA), Ulex europaeus (gorse), Phaseolus vulgaris PHA-L (red kidney bean), Triticum vulgaris (wheat germ), and Concanavalin A (jack bean).
  • Laminin from EHS sarcoma, Poly-L-ornithine (PORN), Poly-L-lysine (PLL), Chondroitinase ABC (chondroitin ABC lyase, E.C. 4.2.2.4. from Proteus vulgaris, protease-free), heparinase and PNA agrose beads were also purchased from Sigma.
  • Horseradish peroxidase (HRP)- conjugated secondary antibodies to rabbit, rat or mouse IgG and IgM were purchased from Amersham and Jackson Labs.
  • Monoclonal antibody 473-HD is a mouse IgM against a chondroitin sulphate epitope on mouse brain proteoglycans (Faissner et al, J. Cell Biol., 126. 783-799, 1994).
  • Rabbit polyclonal anti-versican antibodies were generated against recombinantly expressed human versican fusion proteins.
  • monoclonal anti-L2 antibody (412) from rat (Kruse et al, Nature, 316. 146-148, 1985) and polyclonal antibody 3F8 against phosphacan (Engel et al, J. Comp. Neurol, 366, 34-43, 1996; Meyer-Puttlitz et al, J. Comp. Neurol., 366, 44-54, 1996).
  • MAG myelin-associated glycoprotein
  • Anti-MAG antibody recognizes a 100 kDa band that is highly enriched in fraction 10 but is much weaker in fractions 26 and 32 (Fig 2B).
  • the intensity of the 200 and 220 kDa bands labelled with anti-TN-C was similar to that of the MAG antibody, i.e., enriched in fraction 10 (Fig. 2C).
  • the 160 and 180 kDa bands recognized by the anti-TN-R antibody were present only in the total myelin extract and in fraction 10 (Fig. 2D).
  • the anti-CS mAb 473 recognized 70 kDa band and a slightly small minor band in fractions 26 and 32 but not in the octylglucoside extract of myelin and/or in fraction 10.
  • Enzymatic hydrolysis with chondroitinase ABC and heparinase Proteins were treated with chondroitinase ABC (0.02 U/ml) in 50 mM Tris-acetate (pH 8.0) for 2.5 h at 37°c in the presence of protease inhibitors (5 mM benzamidine, 1 mM iodoacetamide and 5 mM p-tosyl-L-lysine chloromethyl ketone, sodium salt). Heparinase digestion was done according to the manufacturer's instructions. Purification of Anetin.
  • the flow-through was reloaded three times, and the column was subsequently washed with 12 ml Hepes buffer (pH7.5, 0.08% Sodium azide, 10 mM Hepes, 0.15 mM NaCl, 0.1 mM Ca 2+ , and 0.01 mM Mn 2+ ), followed by 12 ml of a high salt buffer (pH7.5, 2 M NaCl, and 20 mM Triethanolamine).
  • the column was eluted with 20 ml of elution buffer (2 M NaCl, 20 mM Trithanolamine, pH7.5, and 0.5 M D-galactose).
  • Concanavalin A (Con- A). Nitrocellulose membranes electro blotted with pooled DEAE fractions 20 to26 after protein separation by SDS-PAGE were probed with the various lectins. All the lectins except Con-A bound only to the 70 kDa bands (not shown).
  • the 70 kDa components are novel phosphocan-versican-related molecules.
  • the 70 kDa bands also reacted with polyclonal antibodies against phosphacan and recombinant versican (Fig. 4A and B). Both these antibodies plus the 473 anti-CS recognized the 70 kDa PNA affinity purified polypeptides (Fig. 4C, D, E).
  • chondroitinase ABC treatment the major 70 kDa proteins were found to have an apparent Mr of 50 kDa (Fig.
  • phosphacan has a molecular weight of 500-600 kDa (core protein 400 kDa), and versican is a very large proteoglycan with a molecular weight of 900 kDa (core protein 400 kDa), the 70 kDa components that we have isolated from CNS myelin are likely to be novel proteins. We call these proteins anetin (collectively).
  • the 2 bands may represent 2 isoforms, or the smaller component may be an altered version of the larger, due to degradation.
  • the 70 kDa proteins inhibit neurite growth.
  • the present invention involved a test that examined effects of the 70 kDa myelin-derived proteins in modulating neurite growth from rat hippocampal and cerebellar granule celleurons.
  • the 70 kDa proteins inhibited neurite growth from neonatal rat cerebellar and hippocampal neurons (Figs. 7 and 8), as well as from cultured NG108-15 cells (Fig. 9). This inhibitory activity was lost after heat denaturation.
  • Tissue culture dishes (Becton Dickinson) with 24 wells were coated with methanol-solubilized nitrocellulose according to Lagenaur and Lemmon (1987) and air-dried in a sterile hood.
  • nitrocellulose and poly-L-lysine (PLL 0.01%) coated dishes were used as described (Xiao et al, Neurosci., 8, 766-782, 1996). The dishes were washed three times with PBS and dried in a sterile hood.
  • test proteins (anetin, denatured (80°c for 30 min) anetin, TN-R, and laminin), each at concentrations of 2 nM, lOnM, and 50nM, were applied in duplicate as 2.5 ⁇ l single spots to the dishes and incubated overnight at
  • Neurites were defined as those processes with a length of at least one cell body diameter. The total neurite length per cell was determined by analysing 50 cells in each of two wells. To determine the number of cells with neurites, 100 neurons in each of two wells were counted per experiment. Raw data from at least three independent experiments were analyzed by ANOVA and by the Newman-Keuls test with P ⁇ 0.05 and P ⁇ 0.01 being considered significant or highly significant, respectively. All graphs comprise data derived from at least three independent experiments.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un système de régulation de la croissance tumorale neuronale et neurale, basé sur une nouvelle protéine, l'arrétine, ainsi que sur les isoformes, fragments et récepteur de celle-ci de cette protéine, et sur des anticorps dirigés contre les constituants de ce système; l'invention concerne également des utilisations diagnostiques, thérapeutiques et de recherche de chacun des aspects de ladite protéine, laquelle présente une masse moléculaire apparente d'environ 70 kDa. Des modes de réalisation de l'invention comprennent la séquence d'acides aminés et des sondes conçues à partir de celle-ci, afin d'obtenir des séquences d'acides nucléiques codant l'arrétine. Dans une variante, on utilise la protéine arrétine marquée, en tant que marqueur destiné à détecter des récepteurs de l'arrétine, lesquels sont ensuite séquencés et utilisés pour obtenir des sondes destinées aux séquences d'acides nucléiques codant les récepteurs de l'arrétine. La présente invention concerne encore des récepteurs de l'arrétine et des fragments de celle-ci, de même que des séquences d'acides nucléiques codant pour de tels récepteurs et fragments, ainsi que des utilisations thérapeutiques et diagnostiques de ces récepteurs, fragments et séquences. Enfin, l'invention concerne et englobe des substances fonctionnant, soit en tant qu'antagonistes, soit en tant qu'agonistes des récepteurs de l'arrétine.
PCT/CA1997/000868 1996-11-15 1997-11-17 Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci WO1998022499A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50442/98A AU5044298A (en) 1996-11-15 1997-11-17 Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2190418 CA2190418A1 (fr) 1996-11-15 1996-11-15 Systeme regulateur pour la croissance des neurones et des tumeurs neuronales; anticorps utilises a cette fin et applications
CA2,190,418 1996-11-15

Publications (3)

Publication Number Publication Date
WO1998022499A2 true WO1998022499A2 (fr) 1998-05-28
WO1998022499A3 WO1998022499A3 (fr) 1998-07-30
WO1998022499A9 WO1998022499A9 (fr) 1998-09-11

Family

ID=4159259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000868 WO1998022499A2 (fr) 1996-11-15 1997-11-17 Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci

Country Status (3)

Country Link
AU (1) AU5044298A (fr)
CA (1) CA2190418A1 (fr)
WO (1) WO1998022499A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053945A1 (fr) * 1998-04-16 1999-10-28 Samuel David Molecules inhibant la croissance neuronale ou leurs derives utilises pour immuniser des mammiferes et ainsi favoriser la regeneration de l'axone
WO2002014537A2 (fr) * 2000-08-14 2002-02-21 Fallon Joan M Diagnostic et traitement de la dysautonomie et autres états de dysautonomie
WO2006111348A1 (fr) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Utilisation d'heparine ou de derives de l'heparine pour la modulation du recepteur nogo controlant la croissance des neurites
US8008036B2 (en) 1999-12-17 2011-08-30 Curemark, Llc Method for identifying autistic individuals amenable to digestive enzyme therapy
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003601A2 (fr) * 1992-08-03 1994-02-17 New York University Clonage, expression et utilisation de neurocan en tant que proteoglycane de sulfate de chondroitine
WO1994017831A1 (fr) * 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central
WO1995020397A1 (fr) * 1994-01-27 1995-08-03 New York University Phosphacane, ses acides nucleiques de codage et ses anticorps
WO1995022344A1 (fr) * 1994-02-21 1995-08-24 Mcgill University Utilisation therapeutique de glycoproteines associees a la myeline (gam)
WO1995026201A1 (fr) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Un proteoglycane de cellule gliale: le brevicane
WO1996032476A1 (fr) * 1995-04-13 1996-10-17 Mount Sinai Hospital Corporation Modulateur de la reponse des cellules neuronales a l'inhibition par la myeline du systeme nerveux central
WO1996032959A1 (fr) * 1995-04-19 1996-10-24 Acorda Therapeutics Modulateurs de la croissance de l'axone et des dendrites du systeme nerveux central, compositions, cellules et procedes dans lesquels ils sont mis en ×uvre et utilises

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003601A2 (fr) * 1992-08-03 1994-02-17 New York University Clonage, expression et utilisation de neurocan en tant que proteoglycane de sulfate de chondroitine
WO1994017831A1 (fr) * 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central
WO1995020397A1 (fr) * 1994-01-27 1995-08-03 New York University Phosphacane, ses acides nucleiques de codage et ses anticorps
WO1995022344A1 (fr) * 1994-02-21 1995-08-24 Mcgill University Utilisation therapeutique de glycoproteines associees a la myeline (gam)
WO1995026201A1 (fr) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Un proteoglycane de cellule gliale: le brevicane
WO1996032476A1 (fr) * 1995-04-13 1996-10-17 Mount Sinai Hospital Corporation Modulateur de la reponse des cellules neuronales a l'inhibition par la myeline du systeme nerveux central
WO1996032959A1 (fr) * 1995-04-19 1996-10-24 Acorda Therapeutics Modulateurs de la croissance de l'axone et des dendrites du systeme nerveux central, compositions, cellules et procedes dans lesquels ils sont mis en ×uvre et utilises

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BODE-LESNIEWSKA ET AL.: "Distribution of the large aggregating proteoglycan versican in adult human tissues" THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 44, no. 4, - April 1996 pages 303-312, XP002062505 cited in the application *
ESKO J.: "GENETIC ANALYSIS OF PROTEOGLYCAN STRUCTURE, FUNCTION AND METABOLISM" CURRENT OPINION IN CELL BIOLOGY, vol. 3, 1991, pages 805-816, XP002062506 *
FRIEDLANDER ET AL.: "THE NEURONAL CHONDROITIN SULFATE PROTEOGLYCAN NEUROCAN BINDS TO THE NEURAL CELL ADHESION MOLECULES Ng-CAM/L1/NILE AND N-CAM, AND INHIBITS NEURONAL ADHESION AND NEURITE OUTGROWTH" THE JOURNAL OF CELL BIOLOGY, vol. 125, no. 3, 1994, pages 669-680, XP002062504 *
SCHWAB M E ET AL: "INHIBITORS OF NEURITE GROWTH" ANNUAL REVIEW OF NEUROSCIENCE, vol. 16, 1 January 1993, pages 565-595, XP000576555 cited in the application *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053945A1 (fr) * 1998-04-16 1999-10-28 Samuel David Molecules inhibant la croissance neuronale ou leurs derives utilises pour immuniser des mammiferes et ainsi favoriser la regeneration de l'axone
US8105584B2 (en) 1999-12-17 2012-01-31 Curemark Llc Method for treating pervasive development disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8613918B2 (en) 1999-12-17 2013-12-24 Curemark Llc Method for treating pervasive development disorders
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US8008036B2 (en) 1999-12-17 2011-08-30 Curemark, Llc Method for identifying autistic individuals amenable to digestive enzyme therapy
US8012930B2 (en) 1999-12-17 2011-09-06 Curemark, Llc Methods of treating pervasive development disorders
US7138123B2 (en) 2000-08-14 2006-11-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
WO2002014537A3 (fr) * 2000-08-14 2002-05-10 Joan M Fallon Diagnostic et traitement de la dysautonomie et autres états de dysautonomie
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
WO2002014537A2 (fr) * 2000-08-14 2002-02-21 Fallon Joan M Diagnostic et traitement de la dysautonomie et autres états de dysautonomie
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2006111348A1 (fr) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Utilisation d'heparine ou de derives de l'heparine pour la modulation du recepteur nogo controlant la croissance des neurites
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US10350229B2 (en) 2005-08-30 2019-07-16 Curemark, Llc Use of lactulose in the treatment of autism
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8318158B2 (en) 2008-04-18 2012-11-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US10272141B2 (en) 2008-04-18 2019-04-30 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8486390B2 (en) 2008-04-18 2013-07-16 Curemark Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US10588948B2 (en) 2008-06-26 2020-03-17 Curemark, Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US10413601B2 (en) 2008-10-03 2019-09-17 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US10736946B2 (en) 2009-01-06 2020-08-11 Galenagen, Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US10716835B2 (en) 2009-10-21 2020-07-21 Curemark, Llc Methods and compositions for the prevention and treatment of influenza
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
US10279016B2 (en) 2011-04-21 2019-05-07 Curemark, Llc Method of treatment of schizophreniform disorder
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Also Published As

Publication number Publication date
CA2190418A1 (fr) 1998-05-15
AU5044298A (en) 1998-06-10
WO1998022499A3 (fr) 1998-07-30

Similar Documents

Publication Publication Date Title
WO1998022499A2 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
WO1998022499A9 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
US5229500A (en) Brain derived neurotrophic factor
US6960559B1 (en) Neurite growth regulatory factors
KR100828058B1 (ko) Ｎｏｇｏ 수용체가 매개하는 축삭 성장의 차단
RU2131926C1 (ru) Днк-фрагмент, кодирующий нейротропный фактор мозга (bdnf), белок bdnf и способ его получения
CA2250075C (fr) Procedes pour diagnostiquer et traiter la maladie d'alzheimer
KR100196540B1 (ko) 축색성장 조절인자
AU1703595A (en) Therapeutic use of myelin-associated glycoprotein (mag)
PT1003545E (pt) Polipéptidos de factor de crescimento que se liga à heparina (hbgf)
JP4649602B2 (ja) 活性依存性向神経第▲ｉｉｉ▼因子（ａｄｎｆ▲ｉｉｉ▼）
ES2259458T3 (es) Persefina humana.
US20030211990A1 (en) Neural regeneration peptides and methods for their use in treatment of brain damage
WO1994017831A9 (fr) Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central
AU5891394A (en) A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
US20100040623A1 (en) Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
WO1993000427A2 (fr) Facteurs regulateurs de la croissance des neurites
JP2010506930A (ja) Ｔｌｒ１４の活性を変調するための組成物および方法
Donoso et al. Immunohistochemistry of retinoblastoma: a review
WO1993001300A1 (fr) Methodes de traitement de maladies des neurones moteurs utilisant des elements de la famille des molecules bdnf/nt-3/ngf
CA2098922A1 (fr) Facteur de differentiation cholinergique neuronal
JP4121852B2 (ja) 癌を予防及び／又は治療するためのタンパク質ｅｓｍ−１のアンタゴニスト化合物の使用、及び癌を予防及び／又は治療するための薬剤の製造
CA2221391A1 (fr) Systeme de regulation du developpement des neurones et des tumeurs neurales, anticorps diriges contre lui et utilisations du systeme
WO1995026201A1 (fr) Un proteoglycane de cellule gliale: le brevicane
KR20030074805A (ko) 뉴로토닌 및 그 이용

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/14-6/14 AND 10/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-6/14 AND 10/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA